Why CRP is a useful biomarker for monitoring COVID-19 Infection & Sepsis

CRP (C-reactive Protein) is an acute-phase, nonspecific marker of inflammation & infection and has been found to broadly correlate with disease severity and treatment response across a variety of infectious and non-infectious conditions1. Its rate of synthesis and secretion increases within hours of acute injury and may reach as high as 20 times the normal [...]

2021-05-24T09:41:56+01:00May 24th, 2021|

QCMD to use virusPHIX-P9™ in its SARS-CoV-2 antigen EQA scheme

QCMD will use the universal biological sample stabilisation virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD has shown that virusPHIX-P9™ is compatible with a variety of SARS-CoV-2 [...]

2021-03-10T13:56:11+00:00March 10th, 2021|

Blood Grouping, Febrile Antigens and TPHA brochure

We are pleased to share our latest product brochure detailing our range of blood grouping (CE and non-CE), febrile antigens, latex agglutination and syphilis/TPHA screening tests. Download brochure here Rapid Labs have been producing high quality blood grouping reagents at our UK laboratory using British manufactured monoclonal cell lines for more than 12 years. We [...]

2021-03-22T14:44:09+00:00January 18th, 2021|

Recent studies show virusPHIX+ inactivates and stabilises SARS-CoV-2

We are proud to be partnering with a number of laboratories around the world for the validation of virusPHIX+™ as a viral transport medium for SARS-CoV-2 testing. Virus Inactivation A recent study from the Roslin Institute in Edinburgh, UK concluded that virusPHIX+™ inactivates SARS-CoV-2 in as little as 10 minutes when treated at a 1:1 [...]

2020-09-22T14:42:45+01:00September 22nd, 2020|

Sanger Institute creates the first cell atlas of mosquito immune cells with the help of vivoPHIX

  Congratulations to Gianmarco Raddi, PhD on the publication of ‘Mosquito cellular immunity at single-cell resolution’ in Science. The study discusses the discovery of new types of mosquito immune cells, including a rare cell type that could be involved in limiting malaria infection, as well as identifying molecular pathways implicated in controlling the malaria parasite. [...]

2020-09-04T16:26:09+01:00September 4th, 2020|

Rapid Labs Ltd secure £80,000 grant from Tendring District Council

Rapid Labs have been awarded an £80,000 grant from Tendring District Council to increase production capacity at their biomedical facility in Little Bentley. The grant has contributed towards the cost of a new ISO 8 clean room facility, which is primarily being used for the manufacture and development of a novel RNA stabiliser and virus [...]

2020-08-17T10:44:58+01:00August 17th, 2020|

Rapid Labs become members of the British In Vitro Diagnostics Association (BIVDA)

We are pleased to announce that Rapid Labs Ltd have been awarded membership of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national industry association for the manufacturers and distributors of IVD products in the UK and currently represent more than 95% of the industry and over a hundred organisations ranging from British [...]

2020-07-30T16:47:10+01:00July 30th, 2020|

Viruses and bacteria successfully inactivated by virusPHIX, vivoPHIX and genoPHIX RNA stabilisation reagents

RNAssist Ltd., is a technology development company based in Cambridge UK specialised in biomolecule stabilisation and microbial inactivation. The range includes genoPHIX™ (for large tissue samples), vivoPHIX™ (for work involving single cell analysis) and virusPHIX™ (for the safe transport and handling of virus samples). Our lead product virusPHIX™ has been shown to stabilise RNA, DNA [...]

2020-06-25T16:50:15+01:00June 23rd, 2020|